S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
What’s next for GM stock: Buybacks and a dividend increase
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
US economic growth for last quarter is revised up to a 5.2% annual rate
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
What’s next for GM stock: Buybacks and a dividend increase
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
US economic growth for last quarter is revised up to a 5.2% annual rate
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
What’s next for GM stock: Buybacks and a dividend increase
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
US economic growth for last quarter is revised up to a 5.2% annual rate
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
The 4 highest-shorted large-cap stocks
What’s next for GM stock: Buybacks and a dividend increase
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
US economic growth for last quarter is revised up to a 5.2% annual rate
General Motors, NetApp rise; Petco, Hormel Foods fall, Wednesday, 11/29/2023

Evaxion Biotech A/S (EVAX) Competitors

$0.78
-0.01 (-1.27%)
(As of 11/29/2023 ET)
Compare
Today's Range
$0.77
$0.82
50-Day Range
$0.68
$1.17
52-Week Range
$0.47
$2.44
Volume
34,156 shs
Average Volume
84,712 shs
Market Capitalization
$21.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

EVAX vs. INAB, ENTX, PLUR, NSTG, AIM, ELEV, FRLN, SRNE, APTO, and CRTX

Should you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include IN8bio (INAB), Entera Bio (ENTX), Pluri (PLUR), NanoString Technologies (NSTG), AIM ImmunoTech (AIM), Elevation Oncology (ELEV), Freeline Therapeutics (FRLN), Sorrento Therapeutics (SRNE), Aptose Biosciences (APTO), and Cortexyme (CRTX). These companies are all part of the "medical" sector.

Evaxion Biotech A/S vs.

Evaxion Biotech A/S (NASDAQ:EVAX) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.

Evaxion Biotech A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, IN8bio has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500.

Evaxion Biotech A/S currently has a consensus price target of $7.00, indicating a potential upside of 797.44%. IN8bio has a consensus price target of $11.00, indicating a potential upside of 1,220.85%. Given IN8bio's higher probable upside, analysts plainly believe IN8bio is more favorable than Evaxion Biotech A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion Biotech A/S
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
IN8bio
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/A-$23.17M-$0.98-0.80
IN8bioN/AN/A-$28.52M-$1.12-0.74

0.6% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 7.4% of IN8bio shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 33.0% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IN8bio received 3 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 64.00% of users gave IN8bio an outperform vote while only 52.00% of users gave Evaxion Biotech A/S an outperform vote.

CompanyUnderperformOutperform
Evaxion Biotech A/SOutperform Votes
13
52.00%
Underperform Votes
12
48.00%
IN8bioOutperform Votes
16
64.00%
Underperform Votes
9
36.00%

In the previous week, IN8bio had 1 more articles in the media than Evaxion Biotech A/S. MarketBeat recorded 4 mentions for IN8bio and 3 mentions for Evaxion Biotech A/S. Evaxion Biotech A/S's average media sentiment score of 1.08 beat IN8bio's score of 0.85 indicating that Evaxion Biotech A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evaxion Biotech A/S
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IN8bio
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

IN8bio's return on equity of -152.81% beat Evaxion Biotech A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Evaxion Biotech A/SN/A -452.78% -126.54%
IN8bio N/A -152.81%-106.33%

Summary

IN8bio beats Evaxion Biotech A/S on 9 of the 14 factors compared between the two stocks.


Get Evaxion Biotech A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion Biotech A/SBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$21.78M$1.96B$4.43B$6.69B
Dividend YieldN/A2.10%2.90%6.97%
P/E Ratio-0.808.66137.1713.60
Price / SalesN/A203.882,650.2097.45
Price / CashN/A24.1285.64141.07
Price / Book2.232.955.375.07
Net Income-$23.17M$27.99M$123.29M$176.65M
7 Day Performance-2.50%1.28%2.18%1.93%
1 Month Performance-17.81%10.61%12.65%9.29%
1 Year Performance-64.22%4.26%3.61%0.26%

Evaxion Biotech A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INAB
IN8bio
2.5308 of 5 stars
$0.74
-15.0%
$11.00
+1,396.6%
-44.1%$23.51MN/A-0.6626Short Interest ↓
ENTX
Entera Bio
1.7283 of 5 stars
$0.73
flat
$10.00
+1,269.9%
+2.9%$21.03M$22,000.00-2.1519Short Interest ↑
News Coverage
Gap Down
PLUR
Pluri
0 of 5 stars
$0.58
+3.6%
N/A-25.5%$24.02M$254,000.00-0.83123Short Interest ↑
NSTG
NanoString Technologies
2.0571 of 5 stars
$0.50
-21.9%
$7.63
+1,425.9%
-91.7%$24.05M$127.26M-0.14703Analyst Downgrade
Gap Up
High Trading Volume
AIM
AIM ImmunoTech
0 of 5 stars
$0.42
flat
N/A+16.5%$20.27M$168,000.00-0.9722Gap Up
ELEV
Elevation Oncology
2.6108 of 5 stars
$0.47
flat
$4.83
+926.6%
-48.7%$19.97MN/A-0.0933Short Interest ↓
Positive News
Gap Up
FRLN
Freeline Therapeutics
2.214 of 5 stars
$5.78
+0.3%
$13.25
+129.2%
-34.0%$25.09M$617,000.00-0.69152Upcoming Earnings
Analyst Downgrade
Short Interest ↓
Analyst Revision
News Coverage
SRNE
Sorrento Therapeutics
1.8074 of 5 stars
$0.04
-19.4%
$13.00
+31,225.3%
-95.9%$19.58M$60.32M0.00799Analyst Report
News Coverage
Gap Up
APTO
Aptose Biosciences
2.3526 of 5 stars
$2.55
-6.9%
$37.67
+1,377.1%
-73.5%$19.23MN/A-0.3231Short Interest ↓
Gap Up
CRTX
Cortexyme
0 of 5 stars
$0.87
-1.1%
N/A+29.5%$26.26MN/A-0.2955Gap Up

Related Companies and Tools

This page (NASDAQ:EVAX) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -